✦ LIBER ✦

Preservation of recall immunity in anti-CD3-treated recent onset type 1 diabetes patients

✍ Scribed by Gonnie M. Alkemade; Robert Hilbrands; Evy Vandemeulebroucke; Daniel Pipeleers; Herman Waldmann; Chantal Mathieu; Bart Keymeulen; Bart O. Roep

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 74 KB
Volume: 27
Category: Article
ISSN: 1520-7552
DOI: 10.1002/dmrr.1273

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A multi-centre randomized trial of two d

A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset Type 1 diabetes (the IMDIAB VI)

✍ Natalia Visalli; Maria G. Cavallo; Alberto Signore; Marco G. Baroni; Raffaella B 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 1 views

Background Intensive insulin therapy is the gold standard by which Type 1 diabetes is treated. In addition to this therapy, administration of nicotinamide (NA) can be bene®cial. This concept is reinforced by the results of a recent meta-analysis of the use of NA in patients with recent-onset Type 1

Effect of heat shock protein peptide Dia

Effect of heat shock protein peptide DiaPep277 on ß-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials

✍ Nanette C. Schloot; Guido Meierhoff; Csaba Lengyel; Gyözö Vándorfi; József Takác 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 255 KB 👁 1 views

## Abstract ## Background Aim of this trial was to test whether heat shock protein peptide DiaPep277 treatment in adult and paediatric patients with recent‐onset type 1 diabetes (T1D) is safe and whether it can preserve endogenous insulin production. ## Methods Two studies were performed in a pr